Streetbeat News

ENTA

Enanta Pharmaceuticals, Inc.

https://www.enanta.com

Industry

Biotechnology

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.

Open

6.25

Mkt cap

128M

Volume

674K

High

6.31

P/E Ratio

-1.10

52-wk high

17.80

Low

6.01

Div yield

N/A

52-wk low

6.01

Enanta Pharmaceuticals announced positive results from a Phase 2 study of zelicapavir for treating RSV in young children, showing antiviral effects.

Portfolio Pulse from

December 09, 2024 | 11:45 am

Enanta Pharmaceuticals (ENTA) reported a Q4 loss of $1.36 per share, missing the Zacks Consensus Estimate of a $1.16 loss. This is a slight increase in loss compared to $1.33 per share a year ago.

Portfolio Pulse from

November 25, 2024 | 11:30 pm

HC Wainwright & Co. analyst Ed Arce has reiterated a Buy rating for Enanta Pharma (NASDAQ:ENTA) and maintained a price target of $27.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 11:17 am

Enanta Pharma (NASDAQ:ENTA) has received mixed analyst ratings over the past three months, with a current average price target of $20.25. Analysts have expressed both bullish and bearish views, with recent actions including maintaining and lowering ratings. Enanta faces financial challenges, including a decline in revenue and below-average profitability metrics.

Portfolio Pulse from Benzinga Insights

October 09, 2024 | 7:02 pm

JMP Securities analyst Roy Buchanan has reiterated a Market Outperform rating for Enanta Pharma (NASDAQ:ENTA) and maintained a price target of $22.

Portfolio Pulse from Benzinga Newsdesk

October 09, 2024 | 6:08 pm

JMP Securities analyst Roy Buchanan has reiterated a Market Outperform rating for Enanta Pharma (NASDAQ:ENTA) and maintained a price target of $22.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2024 | 2:51 pm

Enanta Pharmaceuticals reported positive results from a Phase 2a study of its antiviral EDP-323 for RSV, showing significant reductions in viral load and symptoms. The drug, which has FDA Fast Track designation, demonstrated a favorable safety profile and pharmacokinetics. Enanta is also developing another RSV treatment, zelicapavir.

Portfolio Pulse from Vandana Singh

September 26, 2024 | 6:00 pm

Enanta Pharmaceuticals announced that its Phase 2A study of EDP-323 in healthy adults infected with RSV met primary and secondary endpoints, showing significant reductions in viral load and symptoms compared to placebo.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 10:02 am

JP Morgan analyst Eric Joseph maintains an Underweight rating on Enanta Pharma (NASDAQ:ENTA) and lowers the price target from $11 to $10.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 4:18 pm

HC Wainwright & Co. analyst Ed Arce has reiterated a Buy rating on Enanta Pharma (NASDAQ:ENTA) and maintained a price target of $27.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 10:39 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.